Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: Insights from the faSScinate clinical trial in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 77, Issue 9, 2018, Pages 1362-1371

  Denton, Christopher P ^a   Ong, Voon H ^a   Xu, Shiwen ^a   Chen Harris, Haiyin ^b   Modrusan, Zora ^b   Lafyatis, Robert ^c   Khanna, Dinesh ^d   Jahreis, Angelika ^b   Siegel, Jeffrey ^b   Sornasse, Thierry ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

cytokines; fibroblasts; systemic sclerosis

Indexed keywords

INTERLEUKIN 6 RECEPTOR ALPHA; KRUPPEL LIKE FACTOR 2; PLACEBO; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; INNATE IMMUNITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RNA SEQUENCE; SEQUENCE ANALYSIS; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; ADULT; ANTAGONISTS AND INHIBITORS; BIOPSY; CELL CULTURE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBROBLAST; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SKIN;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; CELLS, CULTURED; DOUBLE-BLIND METHOD; FEMALE; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RECEPTORS, INTERLEUKIN-6; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 85048167375     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-213031     Document Type: Article

References (40)

1. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:134-44.
2. Eckes B, Zigrino P, Kessler D, et al. Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol 2000;19:325-32.
3. Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology 2016;55:1906-10.
4. Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model. Arthritis Rheum 2007;56:2422-31.
5. Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: A pivotal role for fibroblasts as effector cells. Arthritis Res Ther 2013;15:215.
6. Denton CP, Xu S, Welsh KI, et al. Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture. J Rheumatol 1996;23:633-8.
7. Denton CP, Shi-Wen X, Sutton A, et al. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998;114:293-300.
8. Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999;11:503-7.
9. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-11.
10. Varga J, Whitfield ML. Transforming growth factor-beta in systemic sclerosis scleroderma. Frontiers in Bioscience 2009;S1:226-35.
11. O 'Reilly S, Cant R, Ciechomska M, et al. Interleukin-6: A new therapeutic target in systemic sclerosis Clin Transl Immunology 2013;2:e4.
12. Kadono T, Kikuchi K, Ihn H, et al. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998;25:S191-301.
13. Desallais L, Avouac J, Fréchet M, et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 2014;16:R157.
14. De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013;40:435-46.
15. Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012;71:1235-42.
16. Ma F, Li Y, Jia L, et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF /Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One 2012;7:e35144.
17. O'Reilly S, Ciechomska M, Cant R, et al. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-(TGF-) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem 2014;289:9952-60.
18. Wang JH, Zhao L, Pan X, et al. Hypoxia-stimulated cardiac fibroblast production of IL-6 promotes myocardial fibrosis via the TGF-1 signaling pathway. Lab Invest 2016;96:839-52.
19. Elias JA, Lentz V, Cummings PJ. Transforming growth factor-beta regulation of IL-6 production by unstimulated and IL-1-stimulated human fibroblasts. J Immunol 1991;146:3437-43.
20. Michaeloudes C, Sukkar MB, Khorasani NM, et al. TGF-regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2011;300:L295-L304.
21. Khanna D, Denton CP, Jahreis A, et al. Safety anDefficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial. Lancet 2016;387:2630-40.
22. Xu SW, Liu S, Eastwood M, et al. Rac inhibition reverses the phenotype of fibrotic fibroblasts. PLoS One 2009;4:e7438.
23. Shi-wen X, Eastwood M, Stratton RJ, et al. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology 2010;49:259-63.
24. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010;130:694-705.
25. T an AB, Kress S, Castro L, et al. Cellular re-and de-programming by microenvironmental memory: why short TGF-1 pulses can have long effects. Fibrogenesis Tissue Repair 2013;6:12.
26. R enzoni EA, Abraham DJ, Howat S, et al. Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts. Respir Res 2004;5:24.
27. T ourkina E, Gooz P, Oates JC, et al. Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am J Respir Cell Mol Biol 2004;31:28-35.
28. Leroy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med 1972;135:1351-62.
29. Hinchcliff M, Huang CC, Ishida W, et al. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. Clin Exp Rheumatol 2012;30(2 Suppl 71):S86-96.
30. T rojanowska M. What did we learn by studying scleroderma fibroblasts Clin Exp Rheumatol 2004;22(3 Suppl 33):S59-S63.
31. Johnson ME, Mahoney JM, Taroni J, et al. Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts. PLoS One 2015;10:e0114017.
32. Sriram G, Bigliardi PL, Bigliardi-Qi M. Fibroblast heterogeneity and its implications for engineering organotypic skin models in vitro. Eur J Cell Biol 2015;94:483-512.
33. Edlund S, Landström M, Heldin CH, et al. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 2002;13:902-14.
34. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-84.
35. D avenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev 2016;68:357-418.
36. Cockcroft JR, O'Kane KP, Webb DJ. Tissue angiotensin generation and regulation of vascular tone. Pharmacol Ther 1995;65:193-213.
37. Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004;15:2707-19.
38. Kawaguchi Y, Takagi K, Hara M, et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004;50:216-26.
39. Maurer B, Distler A, Suliman YA, et al. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 2014;73:1880-7.
40. Chakraborty D, Šumová B, Mallano T, et al. Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 2017;8:1130.